Exosomics implements NanoFCM’s NanoAnalyzer to provide advanced extracellular vesicles-focused analytical services

January 13, 2020

Exosomics SpA, the leading extracellular vesicles biotech company, today announced that it has implemented NanoFCM Co., Ltd’s NanoAnalyzer instrument to offer sophisticated contract research and measurement services worldwide.

In this strategic partnership, Exosomics becomes NanoFCM’s approved service supplier of nano-flow cytometry measurements. These can be performed as stand-alone or coupled to solutions provided by Exosomics.

The NanoAnalyzer is designed for research use only. It is not for use in diagnostic procedures.

“Thanks to their NanoAnalyzer, Exosomics will be able to supply the widest range of nano-flow cytometry measurements, which are in high demand across Europe and the rest of the world,” said Dr Dimitri Aubert, Managing Director of NanoFCM Co., Ltd. “We are delighted to recommend Exosomics to our close collaborators wishing to access the NanoAnalyzer platform on a punctual basis, or as part of a wider range of services that would accelerate internal research and development capabilities”.

“We believe that by implementing the nano-flow cytometry platform we are once more leading the extracellular vesicles research field and we can offer the widest range of services to Biotech/Pharma and Academic groups,” said Dr Antonio Chiesi, CEO of Exosomics SpA. “This instrument will also allow us to further develop our own liquid biopsy pipeline, which requires the highest level of accuracy and reproducibility”.

About Exosomics
Established in 2012 and hosted in one of the largest and more active bio-parks in Italy, Tuscany Life Sciences. The company is active in the area of Liquid Biopsy in cancer and after several years of R&D work and IP development, is now at commercial stage launching its proprietary and innovative solutions into the molecular diagnostics market. Exosomics’ distinguishing factor is the capability to isolate tumor-derived exosomes through proprietary affinity methods, thus enriching for tumor-derived proteins, DNA and RNA, and therefore significantly improving molecular diagnostics in cancer and allowing early pan-cancer screening. Given that tumor-derived exosomes contain biomarkers identical to those expressed on a cancer cell surface, and poorly expressed in healthy individuals, Exosomics considers exosome-based liquid biopsy as the next generation of cancer diagnostics, which will not only complement but surpass traditional biopsy. The company’s mid/long term goal is to develop a pan-cancer test that will fulfil a critical unmet medical need by enabling early screening of multiple cancer types. Exosomics’ superior know-how and expertise in Liquid Biopsy has attracted several research groups, both Academic and from Biotech/Pharma, who are using its platform and services to address several relevant questions in diagnostics and new therapeutic development. To ensure the highest available quality standards, Exosomics is both ISO 9001 and ISO 13485 certified and GCLP accredited.

About NanoFCM
NanoFCM Inc. is a privately-held company based in Xiamen, China which focuses on the development of high-performance analytical instruments. It has developed a next-generation nanoparticle analysis platform, the NanoAnalyzer, based on nano-flow cytometry. It is unique in its ability to deliver comprehensive measurement (size, concentration and phenotyping) down to 10-40nm, depending on the nature of the substrate. Its high-throughput operation, enables the processing of large numbers of samples required in clinical studies, cutting down the time to publication or to market, whereas its high-sensitivity and high-resolution performance increase the certainty of result. The NanoAnalyzer has already been identified as the new platform of choice for extracellular vesicles analysis, and is finding increased appeal in the analysis of gene therapy vectors, nanoparticle carriers, virus, mitochondria, bacteria and functionalised gold nanoparticles.

Categories: Nanotech, Omics & Genetics, Biotechnology, General Laboratory, Microscopy & Imaging, Drug Discovery & Development, Pharma
Browse more news

Recent releases